Organization

Fennec Pharmaceuticals

Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.

All Programs Therapeutics Devices

Open filtered programs

Programs

linked to organization

Strong Evidence

1 status confirmed

Details Checked

0 open data checks

Company / Institution Links

1 / 1

industry vs non-industry records

Competitive Density

Pipeline Velocity

Completion Signal

100

Programs by Stage

Phase 11

Marketed1

Trial / Program Status

Active1

Marketed1

Modality Mix

Small Molecule2

Indication Coverage

Cisplatin-Induced Hearing Loss2

Hearing Loss2

Ototoxicity1

Program Types

Therapeutic2

Population Tags

cisplatin-ototoxicity2

adult1

otoprotection1

pediatric1

pedmark1

testicular-cancer1

Strong-Evidence Records

1 records

PEDMARK by Fennec Pharmaceuticals

Strong evidence

Small MoleculeMarketedMarketed

Systemic sodium thiosulfate reduces cisplatin-associated ototoxicity by chemically inactivating reactive platinum species after chemotherapy.

Checked Records With Caveats

2 checked · 0 open checks

City of Hope Pedmark adult testicular-cancer otoprotection study

Details checked

Small MoleculePhase 1Active

Intravenous Pedmark/sodium thiosulfate administered 6 hours after cisplatin to reduce cisplatin-induced ototoxicity in adult men receiving cisplatin-based chemotherapy for metastatic testicular germ cell tumors.

Data checks: institution-led-study, active-recruiting